GLP-1 Research Cycle Summary — May 25, 2026
This research cycle tracked major structural, clinical, and regulatory shifts in the GLP-1 and obesity space, highlighting critical milestones that reshape the competitive landscape for pharmaceutical and medical device investors.
1. Clinical Milestones: Retatrutide Breaks the 30% Weight Loss Barrier
Eli Lilly announced landmark Phase 3 TRIUMPH-1 trial results for retatrutide, its first-in-class GIP/GLP-1/glucagon triple agonist. At 80 weeks, the 12 mg dose achieved a record-breaking 28.3% average weight loss (70.3 lbs), with 45.3% of patients achieving ≥30% weight loss—a threshold historically reserved for bariatric surgery. In a 104-week blinded extension, weight loss reached 30.3% (85.0 lbs). While establishing a new efficacy benchmark, retatrutide showed dose-dependent gastrointestinal side effects, leading to an 11.3% discontinuation rate at the highest dose.
- See detailed finding: [[retatrutide-phase3-triumph1-results-30-percent]]
2. Federal Policy Shocks: BALANCE Delayed, Bridge Extended, and Ethics Scrutiny
In a major regulatory twist, CMS indefinitely postponed the permanent BALANCE Model for Medicare Part D (originally set for Jan 2027) due to low commercial plan participation. To compensate, CMS extended the transitional Medicare GLP-1 Bridge Program through December 31, 2027 (launching July 1, 2026), providing eligible Part D beneficiaries with a flat $50 monthly copay for weight loss drugs. However, Bridge spending will not count toward beneficiaries' Part D out-of-pocket maximums or deductibles.
Simultaneously, newly public ethics disclosures showed President Trump's accounts purchased Eli Lilly stock on at least seven occasions in Q1 2026, a period in which his administration cleared the path for Medicare GLP-1 coverage, fast-tracked Lilly's oral pill Foundayo (orforglipron) in 50 days, and proposed a total ban on compounded GLP-1s from the 503B bulk substances list.
- See detailed finding: [[oral-obesity-pills-approved-medicare-glp1-bridge]]
3. Medical Devices: Bariatric Surgery Volume Plunges 34%
A landmark study in JAMA Surgery utilizing IQVIA data from 11.7 million patients confirmed a major structural threat to surgical device manufacturers. Between 2022 and 2025, metabolic bariatric surgery (MBS) utilization plunged by 34.1% (accelerating to a 23% year-on-year decline in 2024), while GLP-1 prescriptions surged by 140.4%. This empirical data highlights that pharmacotherapy is rapidly replacing surgical intervention, directly impacting surgical robotic and medical device players like Intuitive Surgical, Johnson & Johnson, and Medtronic.
- See detailed finding: [[bariatric-surgery-plunges-glp1-prescriptions-surge]]
4. CGM Pivot: Dexcom Launches "Flex" to Capture GLP-1 Users
Continuous glucose monitor (CGM) manufacturers are strategically pivoting to capture non-insulin GLP-1 users. Dexcom announced the launch of Dexcom Flex in Germany, a CGM specifically tailored for adults with Type 2 diabetes who are not on intensive insulin but use basal insulin, oral therapies, or GLP-1 receptor agonists. By reframing the CGM as a companion tool for behavioral lifestyle modifications and food logging, CGM makers are expanding their total addressable market (TAM) to defend against the GLP-1 adoption curve.
- See detailed finding: [[dexcom-launches-flex-cgm-germany-glp1-users]]
5. Application Expansion: Novo Nordisk Strengthens Wegovy's MASH Profile
At the EASL Congress 2026, Novo Nordisk presented robust Phase 3 ESSENCE trial subgroup analyses for semaglutide 2.4 mg (Wegovy) in metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. The data demonstrated a highly favorable hepatic safety profile and consistent efficacy across high-risk, underrepresented populations including menopausal women and Japanese patient cohorts. This clinical progress bolsters Novo's efforts to expand Wegovy's label into chronic liver disease, a massive global market affecting 250 million people.
- See detailed finding: [[novo-nordisk-mash-essence-easl-2026]]